ELI LILLY AND COMPANY Equity Securities, FV-NI, Gain (Loss)
ELI LILLY AND COMPANY (LLY) reported Equity Securities, FV-NI, Gain (Loss) of $46.90 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2025-10-30
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $46.90M, a 58.27% decline year-over-year.
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2025-06-30 was $114.00M.
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2025-03-31 was -$146.70M, a 1016.87% decline year-over-year.
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2024-12-31 was -$20.00M, a 116.49% decline year-over-year.
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for fiscal 2024 was -$49.50M.
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for fiscal 2023 was -$20.20M.
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for fiscal 2022 was -$410.70M, a 332.17% decline from fiscal 2021.
- ELI LILLY AND COMPANY equity securities, fv-ni, gain (loss) for fiscal 2021 was $176.90M, a 87.73% decline from fiscal 2020.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Gain (Loss) 12 month | Equity Securities, FV-NI, Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | $46.90M 10-Q · filed 2025-10-30 | $160.90M derived: sum of 2 quarters · filed 2025-10-30 | $14.10M 10-Q · filed 2025-10-30 | -$5.80M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2025-06-30 | $114.00M 10-Q · filed 2025-08-07 | -$32.80M 10-Q · filed 2025-08-07 | -$52.70M derived: sum of 3 quarters · filed 2025-08-07 | $59.70M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2025-03-31 | -$146.70M 10-Q · filed 2025-05-01 | -$166.70M derived: sum of 2 quarters · filed 2025-05-01 | -$54.30M derived: sum of 3 quarters · filed 2025-10-30 | -$212.20M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2024-12-31 | -$20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $92.40M derived: sum of 2 quarters · filed 2025-10-30 | -$65.50M derived: sum of 3 quarters · filed 2025-10-30 | -$49.50M 10-K · filed 2025-02-19 | ||||
| 2024-09-30 | $112.40M 10-Q · filed 2025-10-30 | -$45.50M derived: sum of 2 quarters · filed 2025-10-30 | -$29.50M 10-Q · filed 2025-10-30 | $91.80M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2024-06-30 | -$157.90M 10-Q · filed 2025-08-07 | -$141.90M 10-Q · filed 2025-08-07 | -$20.60M derived: sum of 3 quarters · filed 2025-08-07 | -$83.50M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $16.00M 10-Q · filed 2025-05-01 | $137.30M derived: sum of 2 quarters · filed 2025-05-01 | $74.40M derived: sum of 3 quarters · filed 2025-05-01 | $9.50M derived: sum of 4 quarters · filed 2025-05-01 | ||||
| 2023-12-31 | $121.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $58.40M derived: sum of 2 quarters · filed 2025-02-19 | -$6.50M derived: sum of 3 quarters · filed 2025-02-19 | -$20.20M 10-K · filed 2025-02-19 | ||||
| 2023-09-30 | -$62.90M 10-Q · filed 2024-10-30 | -$127.80M derived: sum of 2 quarters · filed 2024-10-30 | -$141.50M 10-Q · filed 2024-10-30 | $115.40M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | -$64.90M 10-Q · filed 2024-08-08 | -$78.60M 10-Q · filed 2024-08-08 | $178.30M derived: sum of 3 quarters · filed 2025-02-19 | $55.00M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | -$13.70M 10-Q · filed 2024-04-30 | $243.20M derived: sum of 2 quarters · filed 2025-02-19 | $119.90M derived: sum of 3 quarters · filed 2025-02-19 | $1.00M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $256.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $133.60M derived: sum of 2 quarters · filed 2025-02-19 | $14.70M derived: sum of 3 quarters · filed 2025-02-19 | -$410.70M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | -$123.30M 10-Q · filed 2023-11-02 | -$242.20M derived: sum of 2 quarters · filed 2023-11-02 | -$667.60M 10-Q · filed 2023-11-02 | -$760.80M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | -$118.90M 10-Q · filed 2023-08-08 | -$544.30M 10-Q · filed 2023-08-08 | -$637.50M derived: sum of 3 quarters · filed 2024-02-21 | -$884.30M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$425.40M 10-Q · filed 2023-04-27 | -$518.60M derived: sum of 2 quarters · filed 2024-02-21 | -$765.40M derived: sum of 3 quarters · filed 2024-02-21 | -$550.00M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | -$93.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$340.00M derived: sum of 2 quarters · filed 2024-02-21 | -$124.60M derived: sum of 3 quarters · filed 2024-02-21 | $176.90M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | -$246.80M 10-Q · filed 2022-11-01 | -$31.40M derived: sum of 2 quarters · filed 2022-11-01 | $270.10M 10-Q · filed 2022-11-01 | $807.20M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $215.40M 10-Q · filed 2022-08-04 | $517.00M 10-Q · filed 2022-08-04 | $1.05B derived: sum of 3 quarters · filed 2023-02-22 | $1.20B derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $301.50M 10-Q · filed 2022-04-29 | $838.60M derived: sum of 2 quarters · filed 2023-02-22 | $980.30M derived: sum of 3 quarters · filed 2023-02-22 | $1.56B derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $537.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $678.80M derived: sum of 2 quarters · filed 2023-02-22 | $1.26B derived: sum of 3 quarters · filed 2023-02-22 | $1.44B 10-K · filed 2023-02-22 | -$1.44B 10-K · filed 2021-02-17 | |||
| 2020-09-30 | $141.70M 10-Q · filed 2021-10-27 | $142.50M 10-Q · filed 2020-10-28 | $718.50M derived: sum of 2 quarters · filed 2021-10-27 | $905.10M 10-Q · filed 2021-10-27 | $884.70M 10-Q · filed 2020-10-28 | $1.12B derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-06-30 | $576.80M 10-Q · filed 2021-08-03 | $577.50M 10-Q · filed 2020-07-31 | $763.40M 10-Q · filed 2021-08-03 | $742.20M 10-Q · filed 2020-07-31 | $982.20M derived: sum of 3 quarters · filed 2022-02-23 | $1.01B derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-03-31 | $186.60M 10-Q · filed 2021-04-30 | $164.70M 10-Q · filed 2020-05-01 | $405.40M derived: sum of 2 quarters · filed 2022-02-23 | $431.80M derived: sum of 3 quarters · filed 2022-02-23 | $438.10M derived: sum of 4 quarters · filed 2022-02-23 | |||
| 2019-12-31 | $218.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $245.20M derived: sum of 2 quarters · filed 2022-02-23 | $251.50M derived: sum of 3 quarters · filed 2022-02-23 | $401.20M 10-K · filed 2022-02-23 | -$395.30M 10-K · filed 2020-02-19 | |||
| 2019-09-30 | $26.40M 10-Q · filed 2020-10-28 | $32.70M derived: sum of 2 quarters · filed 2020-10-28 | $182.40M 10-Q · filed 2020-10-28 | $113.10M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-06-30 | $6.30M 10-Q · filed 2020-07-31 | $156.00M 10-Q · filed 2020-07-31 | $86.70M derived: sum of 3 quarters · filed 2021-02-17 | $45.90M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-03-31 | $149.60M 10-Q · filed 2020-05-01 | $80.40M derived: sum of 2 quarters · filed 2021-02-17 | $39.60M derived: sum of 3 quarters · filed 2021-02-17 | $60.40M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2018-12-31 | -$69.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$110.00M derived: sum of 2 quarters · filed 2021-02-17 | -$89.20M derived: sum of 3 quarters · filed 2021-02-17 | -$72.60M 10-K · filed 2021-02-17 | -$20.10M 10-K · filed 2019-02-19 | |||
| 2018-09-30 | -$40.80M 10-Q · filed 2019-10-25 | -$20.00M derived: sum of 2 quarters · filed 2019-10-25 | -$3.40M 10-Q · filed 2019-10-25 | |||||
| 2018-06-30 | $20.80M 10-Q · filed 2019-08-02 | $38.60M 10-Q · filed 2019-08-02 | ||||||
| 2018-03-31 | $18.70M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |